Recall of Quetiapine oral suspension (unlicensed medicine), manufactured by Eaststone Limited

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 1 medicines recall for Quetiapine oral suspension (unlicensed medicine). Eaststone Limited is initiating a recall of all batches of Quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients.

Eaststone Limited have informed MHRA that the formula they have used to manufacture all batches of Quetiapine oral suspension products is incorrect. The active content is twice the amount that it should be which could lead to overdosing.  

The recall includes batches that have expired. Any patients who have taken batches, including both expired and non-expired should be reviewed.

Patients should be advised not to stop any treatments without consulting their relevant healthcare professional and a treatment review should be initiated as soon as possible.

The alert contains actions to be completed by the 5^th February which should be coordinated by the Chief Pharmacist/Superintendent Pharmacist or Responsible Pharmacist and Dispensing GPs in the first instance, with support from other healthcare professionals.

Further information, actions, advice and details of the affected batches can be found on the MHRA website.